Clinical spectrum of primary hemophagocytic lymphohistiocytosis: experience of reference centers in Central and Southeast Anatolia
Annals of Hematology · 2024
DOI: 10.1007/s00277-024-06087-y ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Annals of Hematology, 2024. Verfasst von Şefika Akyol und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Hematology and Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey. Hauptthemen laut MEDLINE: Lymphohistiocytosis, Hemophagocytic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease, with a high mortality if left untreated. In addition, the disease has unique diagnostic challenges. Therefore, despite the existing guidelines on management, current clinical practice data is informative on the course and outcome. Herein, a retrospective chart review study was conducted through the collaboration of six centers, located in central and southeastern Türkiye. The demographical data, laboratory results, and treatment outcomes were evaluated. Eighty-three patients were enrolled in the study. The mean age was 2 years, whereas the median age was 8 months with a range of a minimum of 1 week and a maximum of 12.6 years. Consanguineous marriage, history of sibling death, and familial history of similar disease were determined in 72.2% (n:60), 34.9% (n:29), and 39.8% (n:33) of the patients, respectively. The most common presentation was fever, followed by hepatosplenomegaly on admission. Disease-causing familial HLH variants were identified in 60.2% (n:50) of the patients. Hematopoietic stem cell transplantation (HSCT) was performed in 39.7% (n:33) of the cohort. The 2-year overall survival (OS) rate was 62.4% for the whole group. Comparing the patients who received HSCT and those who did not; the HSCT group had a 2-year OS of 84.7%, which was significantly better than patients who did not receive HSCT had a 2-year OS of 47.1% (p:0.001). Despite the improvement in HLH diagnostics and treatment options over the last decade, early death remains a leading problem for the survival of these patients. Therefore, appropriate assessment of the patients in experienced centers and HSCT are pivotal for better outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pediatric Hematology and Oncology, Erciyes University Faculty of Medicine, Kayseri, Turkey.
- Division of Pediatric Hematology and Oncology, Health Sciences University, Antalya Training and Research Hospital, Antalya, Turkey.
- Division of Pediatric Hematology and Oncology, Necmettin ERBAKAN University Faculty of Medicine, Tıp Fakültesi, Konya, Turkey.
- Division of Pediatric Hematology and Oncology, Van Yüzüncü Yıl University Faculty of Medicine, Van, Turkey.
- Division of Pediatric Hematology and Oncology, Gaziantep University Faculty of Medicine, Gaziantep, Turkey.
- Division of Pediatric Hematology and Oncology, Sütçü İmam University Faculty of Medicine, Kahramanmaraş, Turkey.
Zitieren
APA
Akyol, Ş., Yılmaz, E., Tokgöz, H., Karaman, K., Pekpak, E., Özcan, A., Şi Mşek, A., Arslan, B., Ören, A. C., Gökçeli, H. S., Acıpayam, C., Güzel, T., Tuncel, D. A., Gök, V., Arslan, K., Eken, A., Canatan, H., Akbayram, S., Karakükcü, M., …, & Ünal, E. (2024). Clinical spectrum of primary hemophagocytic lymphohistiocytosis: experience of reference centers in Central and Southeast Anatolia. Annals of Hematology. https://doi.org/10.1007/s00277-024-06087-y
Vancouver
Akyol Ş, Yılmaz E, Tokgöz H, Karaman K, Pekpak E, Özcan A, et al. Clinical spectrum of primary hemophagocytic lymphohistiocytosis: experience of reference centers in Central and Southeast Anatolia. Annals of Hematology. 2024. doi:10.1007/s00277-024-06087-y
BibTeX
@article{Akyol2024,
author = {Akyol, Şefika and Yılmaz, Ebru and Tokgöz, Hüseyin and Karaman, Kamuran and Pekpak, Esra and Özcan, Alper and Şi Mşek, Ayşe and Arslan, Bilal and Ören, Ayşe Ceyda and Gökçeli, Habibe Selver and Acıpayam, Can and Güzel, Turan and Tuncel, Defne Ay and Gök, Veysel and Arslan, Kübra and Eken, Ahmet and Canatan, Halit and Akbayram, Sinan and Karakükcü, Musa and Aycan, Nur and Çalışkan, Ümran and Patıroğlu, Türkan and Özdemi R, Mehmet Akif and Chiang, Samuel C C and Bryceson, Yenan T and Ünal, Ekrem},
title = {Clinical spectrum of primary hemophagocytic lymphohistiocytosis: experience of reference centers in Central and Southeast Anatolia},
journal = {Annals of Hematology},
year = {2024},
doi = {10.1007/s00277-024-06087-y}
}
EUVIMED